Teleflex Incorporated (NYSE:TFX) CFO Thomas E. Powell sold 7,500 shares of the business’s stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $332.90, for a total transaction of $2,496,750.00. Following the completion of the transaction, the chief financial officer now directly owns 18,197 shares of the company’s stock, valued at approximately $6,057,781.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of TFX stock traded up $0.87 during trading hours on Thursday, reaching $341.70. 181,553 shares of the company’s stock were exchanged, compared to its average volume of 330,748. The stock’s 50 day moving average is $357.58 and its 200-day moving average is $320.20. The company has a market cap of $15.76 billion, a price-to-earnings ratio of 34.52, a P/E/G ratio of 2.13 and a beta of 1.00. The company has a current ratio of 2.52, a quick ratio of 1.59 and a debt-to-equity ratio of 0.82. Teleflex Incorporated has a fifty-two week low of $226.02 and a fifty-two week high of $373.90.
Teleflex (NYSE:TFX) last issued its quarterly earnings results on Thursday, August 1st. The medical technology company reported $2.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.59 by $0.07. The business had revenue of $652.50 million for the quarter, compared to the consensus estimate of $637.06 million. Teleflex had a return on equity of 18.57% and a net margin of 10.78%. The business’s quarterly revenue was up 7.0% on a year-over-year basis. During the same period in the prior year, the firm posted $2.47 earnings per share. Equities analysts anticipate that Teleflex Incorporated will post 11.03 EPS for the current year.
TFX has been the subject of a number of recent research reports. ValuEngine downgraded shares of Teleflex from a “buy” rating to a “hold” rating in a research note on Tuesday, September 10th. JMP Securities boosted their price objective on shares of Teleflex from $325.00 to $395.00 and gave the stock a “market outperform” rating in a research note on Monday, August 5th. Wells Fargo & Co initiated coverage on shares of Teleflex in a research note on Tuesday, June 11th. They issued an “outperform” rating and a $345.00 price objective for the company. Morgan Stanley boosted their price objective on shares of Teleflex from $345.00 to $392.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Finally, Svb Leerink boosted their price objective on shares of Teleflex from $395.00 to $405.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 4th. Three investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $374.45.
Hedge funds have recently modified their holdings of the company. Reilly Financial Advisors LLC acquired a new position in shares of Teleflex during the second quarter worth $25,000. Icon Wealth Partners LLC purchased a new stake in shares of Teleflex during the first quarter valued at $37,000. Harvest Fund Management Co. Ltd purchased a new stake in shares of Teleflex during the second quarter valued at $46,000. CSat Investment Advisory L.P. grew its holdings in shares of Teleflex by 97.4% during the second quarter. CSat Investment Advisory L.P. now owns 150 shares of the medical technology company’s stock valued at $50,000 after buying an additional 74 shares during the last quarter. Finally, Cullen Frost Bankers Inc. purchased a new stake in shares of Teleflex during the second quarter valued at $52,000. 90.40% of the stock is currently owned by institutional investors and hedge funds.
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease.
Featured Story: What is an investor looking for in an SEC filing?
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.